At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure
The University of Texas Health Science Center at San Antonio·interventional·Posted Jan 19, 2015·Updated Apr 10, 2020
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and TH-302 for Glioblastoma. Completed, enrolled 35 participants across 2 sites.
Detailed Summary
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMay 2015
Primary CompletionJan 2019
Study CompletionDec 2019
TodayJul 2026
First PostedJan 19, 2015
Enrollment StartMay 1, 2015
Primary CompletionJan 4, 2019
Study CompletionDec 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.5 years ago
Interventions
Bevacizumabdrug
10mg/kg
TH-302drug
670mg/m2